Clinical Trials Browser

Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2 Active not recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT05362773 2026-01-13

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1 Recruiting

130 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00412594 2025-12-22

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase 2 Recruiting

150 enrolled

Other hematologic neoplasm

Leukemia, Hairy Cell

Clinical Trials

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

ZUMA-25

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia